V1014
Anti-Vascular Endothelial Growth Factor Receptor 2 antibody produced in goat
affinity isolated antibody, lyophilized powder
Synonym(e):
Anti-Flk-1, Anti-VEGF R2
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empfohlene Produkte
Biologische Quelle
goat
Qualitätsniveau
Konjugat
unconjugated
Antikörperform
affinity isolated antibody
Antikörper-Produkttyp
primary antibodies
Klon
polyclonal
Form
lyophilized powder
Speziesreaktivität
mouse
Methode(n)
flow cytometry: 3-10 μg/mL (106 cells)
immunohistochemistry: 5-15 μg/mL using cells and tissues
neutralization: suitable
western blot: 0.1-0.2 μg/mL
UniProt-Hinterlegungsnummer
Lagertemp.
−20°C
Posttranslationale Modifikation Target
unmodified
Angaben zum Gen
mouse ... Kdr(16542)
Allgemeine Beschreibung
Vascular endothelial growth factors receptors (VEGF Rs) are receptor tyrosine kinases that bind to VEGF that plays important role in embryonic vasculogenesis, angiogenesis and homeostasis. VEGF R2 has the ability to form heterodimers with VEGF R1 and VEGF R3. The binding of VEGF to VEGF R2 results in activation of tyrosine amino acids of the cytoplasmic tail of the receptor. This interaction results in the activation of MAPK, PI3K, PKC, FAK and Src kinase pathways. The biological roles of VEGF R2 include in epithelial cell growth, proliferation, survival, migration and vascular permeability and angiogenesis. Due to its role in promoting migration and angiogenesis, VEGF R2 has been implicated in breast and prostate cancer
Anti-Vascular Endothelial Growth Factor Receptor-2 recognizes mouse VEGF R2.
Anti-Vascular Endothelial Growth Factor Receptor-2 recognizes mouse VEGF R2.
Spezifität
The antibody has the ability to neutralize the biological activity of recombinant mouse VEGF R2. It demonstates approximately 40% cross-reactivity with recombinant human VEGF R2, 2% cross-reactivty with recombinant mouse VEGF R1, and no cross-reactivity with recombinant human VEGF R1 and VEGF R3.
Immunogen
purified recombinant mouse VEGF R2 extracellular domain expressed in NSO cells.
Anwendung
Anti-Vascular Endothelial Growth Factor Receptor 2 antibody may be used in immunoblotting at a working concentration of 0.1-0.2 μg/ml. For flow cytometry the recommended concentration is 3-10 μg/ml. The immunohistochemistry of cells and tissues, a working concentration of 5-15 μg/ml may be used. For neutralization reactions, ND50 of 0.1-0.3 μg/ml is recommended.
Physikalische Form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Lagerklassenschlüssel
11 - Combustible Solids
WGK
WGK 1
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Persönliche Schutzausrüstung
Eyeshields, Gloves, type N95 (US)
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Javier Carbajo-Lozoya et al.
Cellular signalling, 24(6), 1261-1269 (2012-03-01)
Vascular endothelial growth factor (VEGF) is a main stimulator of pathological vessel formation. Nevertheless, increasing evidence suggests that Angiotensin II (Ang II) can play an augmentory role in this process. We thus analyzed the contribution of the two Ang II
P Berger et al.
Swiss medical weekly, 141, w13318-w13318 (2011-12-20)
Vascular endothelial growth factors (VEGFs) regulate blood and lymph vessel formation through activation of the type V receptor tyrosine kinases VEGFR-1, -2 and -3. In addition, VEGFs interact with co-receptors such as neuropilins, integrins, semaphorins or heparansulfate glycosaminoglycans. Ligand binding
Takayuki Jujo Sanada et al.
PloS one, 14(3), e0214654-e0214654 (2019-03-30)
Pulmonary intimal sarcoma (PIS) constitutes a rare sarcoma originating from the intimal cells of pulmonary arteries. The pathogenesis of PIS remains to be elucidated and specific treatments have not been established; therefore, prognosis is generally poor. The purpose of our
Rachel L Padget et al.
Mechanisms of development, 156, 8-19 (2019-02-24)
Blood vessel maturation, which is characterized by the investment of vascular smooth muscle cells (vSMCs) around developing blood vessels, begins when vessels remodel into a hierarchy of proximal arteries and proximal veins that branch into smaller distal capillaries. The ultimate
Shanchun Guo et al.
Biochimica et biophysica acta, 1806(1), 108-121 (2010-05-14)
Investigations over the last decade have established the essential role of growth factors and their receptors during angiogenesis and carcinogenesis. The vascular endothelial growth factor receptor (VEGFR) family in mammals contains three members, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4)
Artikel
Cancer stem cell media, spheroid plates and cancer stem cell markers to culture and characterize CSC populations.
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.